Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated with red blood cell transfusions is usually reduced, but it is unclear whether transfusion dose density is an independent prognostic factor. The European MDS Registry collects prospective data at 6-mo...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Haematologica
Auteurs principaux: de Swart, Louise, Crouch, Simon, Hoeks, Marlijn, Smith, Alex, Langemeijer, Saskia, Fenaux, Pierre, Symeonidis, Argiris, Cermâk, Jaroslav, Hellström-Lindberg, Eva, Stauder, Reinhard, Sanz, Guillermo, Mittelman, Moshe, Holm, Mette Skov, Malcovati, Luca, Mądry, Krzysztof, Germing, Ulrich, Tatic, Aurelia, Savic, Aleksandar, Almeida, Antonio Medina, Gredelj-Simec, Njetocka, Guerci-Bresler, Agnes, Beyne-Rauzy, Odile, Culligan, Dominic, Kotsianidis, Ioannis, Itzykson, Raphael, van Marrewijk, Corine, Blijlevens, Nicole, Bowen, David, de Witte, Theo
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049377/
https://ncbi.nlm.nih.gov/pubmed/31171638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.212217
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires